Product Highlight - Amnoz

30 Nov 2022
Product Highlight - Amnoz
YOUR CHOICE FOR BETTER BLOOD PRESSURE CONTROL
• Available in 5 mg and 10 mg
• First-line treatment for hypertension and angina
• Long half-life at 30 to 50 hours and is consistent with once-daily dosing
• Bioequivalent to the originator

References:
•Amnoz Tablet 5 mg, 10 mg Package Insert, July 2021.
•Integrated Study Report for Oral Bioequivalence study of Pharmaniaga Amlodipine 10 mg tablet, Pharmaniaga Manufacturing Berhad, Malaysia and Norvasc (amlodipine) 10 mg tablet of Pfizer Australia Pty. Ltd., Australia, in healthy, adult, human subjects under fasting condition.
•Fares H, DiNicolantonio JJ, O’Keefe JH, et al. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. 2016.

Related MIMS Drugs

Editor's Recommendations